Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2007

View Archived Issues

Huya licenses ex-China rights to chidamide

GSK reviews 2006 progress, anticipates 2007 milestones

Exelixis updates EXEL-2819 profile

IRBM presents second-generation class I HDAC inhibitors at recent congress

GPI-1046 inhibits HIV-associated sensory neuropathy in vivo

NYVAC-C HIV vaccine assessed with and without DNA-C in healthy volunteers

T-cell increases seen in HIV-infected patients given recombinant interleukin-7

New treatment options for neurological disorders disclosed in recent patent literature

Novel factor Xa inhibitor described at GSK

Phase Ib/II data on single agent ADH-1 presented

Dyax and Glenmark to cooperate on discovery of therapeutic antibodies

NGX-267 studied in multiple-dose phase I trial

BioLineRx in-licenses novel drug delivery system

First human microdosing trial completes for I-3D compound

Novel treatment strategy for glaucoma and ocular hypertension claimed by Allergan

Novel therapeutic strategies for metabolic disorders described in recent patents

ObeCure begins phase II study for OBE-101 to prevent Zyprexa weight gain

Cell Therapeutics seeks SPA for pixantrone trial in indolent NHL

Enzo studies gene therapy for HIV-1 in phase I/II trial

IND filing for pivotal study of improved octreotide formulation

Allegra Oral Suspension now available for children

GTC grants expanded license to PharmAthene in support of Protexia

Virax grants Transgene access to Co-X-Gene technology

SPA agreement for phase III EOquin trials in noninvasive bladder cancer

Amitiza begins U.S. postmarking studies, Japanese phase I study

MEM-354 begins phase IIa study for Alzheimer's disease

CYT003-QbG10 significantly improves allergy symptoms in hay fever patients

Tyrima safe and well tolerated in phase I trial